Stocks CNBC 29d ago

Amgen CEO says weight loss drug can address 'patient persistence issue'

Market Intelligence Analysis

AI-Powered
Why This Matters

Amgen CEO Bob Bradway expressed optimism about the company's weight loss drug, citing its potential to address the 'patient persistence issue' in the market.

Market Impact

Market impact analysis based on bullish sentiment with 80% confidence.

Sentiment
Bullish
AI Confidence
80%
Time Horizon
Short Term

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

Amgen CEO Bob Bradway discussed his company's weight loss drug in an interview with CNBC's Jim Cramer.

Continue Reading
Full article on CNBC
Read Full Article

Related Articles

Stocks 16m ago

Airbnb expects a continued travel rebound this year, as it banks on …

Airbnb expects a continued travel rebound this year, driven by new services, and is expanding …
Stocks 41m ago

Instacart stock pops 14% on revenue beat, rosy guidance

Instacart's stock price surged 14% after the company reported better-than-expected revenue and optimistic guidance, driven …
Stocks 45m ago

Rivian tops Q4 expectations, expects losses to continue amid production increase

Rivian has exceeded Q4 expectations and plans to increase vehicle deliveries by 47-59% in 2026, …
Stocks 42m ago

Pinterest shares tank 20% on earnings miss, weak guidance

Pinterest's stock price has declined by 20% due to the company's earnings miss and weak …
Stocks 47m ago

Airbnb reports fourth-quarter results that beat on revenue

Airbnb reported a strong fourth-quarter performance, beating revenue expectations and providing optimistic guidance, indicating a …
Stocks 57m ago

NASA spacesuit maker backed by Donald Trump Jr.'s venture firm raises $350 …

A space company backed by Donald Trump Jr.'s venture firm has raised $350 million to …
Original article published by CNBC on January 14, 2026.
Analysis and insights provided by AnalystMarkets AI.